DURECT Corporation (DRRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
DRRX POWR Grades
- Value is the dimension where DRRX ranks best; there it ranks ahead of 65% of US stocks.
- The strongest trend for DRRX is in Momentum, which has been heading down over the past 31 weeks.
- DRRX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
DRRX Stock Summary
- With a one year PEG ratio of 407.95, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 91.32% of US stocks.
- With a price/sales ratio of 11.31, Durect Corp has a higher such ratio than 83.49% of stocks in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DRRX comes in at -19.73% -- higher than that of just 13.48% of stocks in our set.
- Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are ELSE, INGN, ESP, WHLM, and EEFT.
- DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DRRX Valuation Summary
- DRRX's price/sales ratio is 11.4; this is 216.67% higher than that of the median Healthcare stock.
- DRRX's price/sales ratio has moved down 131.6 over the prior 243 months.
- DRRX's price/sales ratio has moved down 131.6 over the prior 243 months.
Below are key valuation metrics over time for DRRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DRRX | 2018-05-09 | 6.5 | 10.3 | -80.5 | -207.1 |
| DRRX | 2016-05-16 | 9.1 | 16.0 | -6.4 | -7.7 |
| DRRX | 2015-09-02 | 14.1 | 10.9 | -10.7 | -12.5 |
| DRRX | 2015-02-20 | 5.8 | 4.8 | -5.3 | -6.1 |
| DRRX | 2006-07-11 | 7.5 | 5.5 | -11.3 | -15.6 |
| DRRX | 2002-06-27 | 54.9 | 4.2 | -7.4 | -7.2 |
DRRX Growth Metrics
- Its 3 year price growth rate is now at -31.28%.
- Its year over year net cashflow from operations growth rate is now at -1037.98%.
- Its 3 year revenue growth rate is now at 6.95%.
The table below shows DRRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 29.548 | -36.553 | -0.768 |
| 2020-12-31 | 30.111 | -38.704 | -0.582 |
| 2020-09-30 | 41.987 | -26.347 | -9.173 |
| 2020-06-30 | 50.067 | 1.126 | -1.831 |
| 2020-03-31 | 28.208 | 3.897 | -23.396 |
| 2019-12-31 | 29.564 | 11.101 | -20.578 |
DRRX Price Target
For more insight on analysts targets of DRRX, see our DRRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.00 | Average Broker Recommendation | 1.4 (Strong Buy) |
DRRX Stock Price Chart Interactive Chart >
DRRX Price/Volume Stats
| Current price | $1.41 | 52-week high | $2.95 |
| Prev. close | $1.51 | 52-week low | $1.28 |
| Day low | $1.35 | Volume | 955,005 |
| Day high | $1.47 | Avg. volume | 1,353,826 |
| 50-day MA | $1.59 | Dividend yield | N/A |
| 200-day MA | $1.91 | Market Cap | 320.64M |
DURECT Corporation (DRRX) Company Bio
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
Latest DRRX News From Around the Web
Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021. |
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual SummitDURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021. |
Here's What DURECT Corporation's (NASDAQ:DRRX) Shareholder Ownership Structure Looks LikeThe big shareholder groups in DURECT Corporation ( NASDAQ:DRRX ) have power over the company. Generally speaking, as a... |
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 International Liver Conference (EASL) being held virtually June 23-26, 2021. |
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26 , 2021. |
DRRX Price Returns
| 1-mo | -13.50% |
| 3-mo | -25.79% |
| 6-mo | -31.55% |
| 1-year | -27.32% |
| 3-year | -4.08% |
| 5-year | -27.32% |
| YTD | -31.88% |
| 2020 | -45.53% |
| 2019 | 691.67% |
| 2018 | -47.83% |
| 2017 | -31.34% |
| 2016 | -39.37% |
Continue Researching DRRX
Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...